Search for Clinical Trial Results

Lymphoma, Extranodal NK-T-Cell - 15 Studies Found
Status | Study |
Recruiting |
Study Name: Combine GELOX With Concurrent Radiation Therapy for Patients With Stage IE/IIE ENKTL Condition: Lymphoma, Extranodal NK-T-Cell Date: 2014-03-02 Interventions:
|
Not yet recruiting |
Study Name: 18F-FDG PET/CT-based Prognostic Model for Predicting Outcome in Patients With Natural Killer/T-cell Lymphoma Condition: Lymphoma, Extranodal NK-T-Cell Date: 2017-02-09 Interventions: Device: 18F-FDG PET/ CT 18F-FDG PET/CT will be conducted before, during and after chemotherapy. Patients |
Not yet recruiting |
Study Name: Evaluating 18F-FDG PET/CT With Liver SUVmax-based Criteria for Prognosis of Patients With Natural Killer/T-cell Lymphoma Condition: Lymphoma, Extranodal NK-T-Cell Date: 2017-02-09 Interventions: Device: 18F-FDG PET/CT 18F-FDG PET/CT will be conducted before, during and after chemotherapy. Patients |
Terminated |
Study Name: P-Gemox Regimen as First-line Chemotherapy in NK/T Lymphoma Patiens Condition: Lymphoma, Extranodal NK-T-Cell Date: 2015-08-24 Interventions:
|
Recruiting |
Study Name: GLIDE Regiment Followed by ASCT for Aggressive NK/T Cell Lymphoma Condition: Lymphoma, Extranodal NK-T-Cell Date: 2017-05-02 Interventions: Drug: GLIDE The dose and schedule of GLIDE chemotherapy was as follows: gemcitabine 800 mg/m 2 days 1, 8 |
Not yet recruiting |
Study Name: Differences Between Chidamide Taken Daily and Twice a Week in Therapeutic Effect,Pharmacokinetics, Pharmacodynamics and EB Virus Activation Condition:
Date: 2016-08-20 Interventions:
|
Recruiting |
Study Name: Cellular Immunotherapy Treatment Antigen-Directed for EBV Lymphoma Condition:
Date: 2013-09-13 Interventions: Biological: CMD-003 Autologous EBV-specific T-cells |
Active, not recruiting |
Study Name: Campath-1H and EPOCH to Treat Non-Hodgkin's T- and NK-Cell Lymphomas Condition:
Date: 2003-09-17 Interventions:
|
Recruiting |
Study Name: VP-16, Ifosfamide, Dexamethasone, L-asparaginase Chemotherapy in Patients With Extranodal Natural Killer T Cell Lymphoma (VIDL+ASCT) Condition: Extranodal NK-T-Cell Lymphoma Date: 2015-09-06 Interventions:
|
Recruiting |
Study Name: Social Media-based Active Self-report on Incidence and Outcomes of Adverse Events in NK/TCL Patients Condition: Extranodal NK-T-Cell Lymphoma, Nasal Type Date: 2017-03-09 Interventions: Combination Product: L-Asparaginase or or Pegaspargase containing chemotherapy Patients receive at least |